Carcinoma, Renal Cell

• 

  Subject Areas on Research

  • "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. 
  • De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-center Experience. 
  • A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). 
  • A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. 
  • A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. 
  • A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. 
  • A comparison of analytic approaches for investigating the obesity paradox in kidney cancer. 
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 
  • A novel murine model of human renal cell carcinoma spinal metastasis. 
  • A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events. 
  • A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. 
  • A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. 
  • A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • ACR Appropriateness Criteria Renal Cell Carcinoma Staging. 
  • ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. 
  • ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update. 
  • ACR Appropriateness Criteria® Staging of Renal Cell Carcinoma: 2022 Update. 
  • ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. 
  • ASO Author Reflections: Long-Term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma. 
  • Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. 
  • Accuracy in staging of renal cell carcinoma involving vena cava. 
  • Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). 
  • Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 
  • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. 
  • Adjusting for misclassification in a stratified biomarker clinical trial. 
  • Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. 
  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. 
  • Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. 
  • Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. 
  • Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. 
  • Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. 
  • Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma. 
  • Altered expression of transforming growth factor-alpha: an early event in renal cell carcinoma development. 
  • Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. 
  • An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. 
  • An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC). 
  • An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. 
  • An active learning approach for rapid characterization of endothelial cells in human tumors. 
  • Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Analysis of renal cell transformation following exposure to trichloroethene in vivo and its metabolite S-(dichlorovinyl)-L-cysteine in vitro. 
  • Anaplastic renal cell carcinoma following neuroblastoma. 
  • Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. 
  • Anti-angiogenic therapy in renal cell cancer. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 
  • Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. 
  • BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bilateral renal cell carcinoma in a child. 
  • Bilateral renal cell carcinoma metastasis in the oral cavity. 
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. 
  • Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer. 
  • Body mass index and the clinicopathological characteristics of clinically localized renal masses-An international retrospective review. 
  • Bosniak category IIF and III cystic renal lesions: outcomes and associations. 
  • Broadening the View of Germline Mutations in Kidney Cancer. 
  • CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. 
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. 
  • Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. 
  • Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Caval thrombosis: imaging and managing a moving target. 
  • Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. 
  • Cell-programmed nutrient partitioning in the tumour microenvironment. 
  • Characteristics and outcomes of tumors arising from the distal nephron. 
  • Characteristics of patients diagnosed with both melanoma and renal cell cancer. 
  • Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. 
  • Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. 
  • Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma. 
  • Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. 
  • Cigarette smoking is associated with advanced renal cell carcinoma. 
  • Clear cell hidradenoma: a mimic of metastatic clear cell tumors. 
  • Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. 
  • Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical impact of an adaptive statistical iterative reconstruction algorithm for detection of hypervascular liver tumours using a low tube voltage, high tube current MDCT technique. 
  • Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). 
  • Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. 
  • Clinical predictors of renal mass pathological features. 
  • Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. 
  • Clinicopathological characteristics of surgically treated localized renal masses in patients previously exposed to chemotherapy. 
  • Collecting duct carcinoma of the kidney. 
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 
  • Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. 
  • Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. 
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. 
  • Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. 
  • Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. 
  • Concomitant renal cell carcinoma and metastatic epithelioid angiosarcoma with microangiopathy. 
  • Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. 
  • Cost-effectiveness of dual-energy CT versus multiphasic single-energy CT and MRI for characterization of incidental indeterminate renal lesions. 
  • Costimulation, coinhibition and cancer. 
  • Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. 
  • Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. 
  • Cytogenetic and molecular correlates between rodent and human renal cell carcinoma. 
  • Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. 
  • Debulking nephrectomy in metastatic renal cancer. 
  • Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. 
  • Deferred systemic therapy in patients with metastatic renal cell carcinoma. 
  • Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. 
  • Diagnosis of metastatic renal cell carcinoma on fine-needle aspiration cytology. 
  • Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Donor-origin cancer in renal transplant recipients from deceased donors: worth gambling? 
  • Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. 
  • Editorial Comment on: "Ten-Year Experience with Percutaneous Cryoablation of Renal Tumors: Tumor Size Predicts Disease Progression" by Pickersgill et al. 
  • Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. 
  • Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma. 
  • Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. 
  • Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Epidermal growth factor receptor gene analysis in renal cell carcinoma. 
  • Erythema nodosum in a patient with renal cell carcinoma treated with interleukin 2 and lymphokine-activated killer cells. 
  • Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. 
  • Estrogen treatment enhances hereditary renal tumor development in Eker rats. 
  • Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study. 
  • Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. 
  • Evaluation of the paracrine and endocrine effects of genitourinary tumor produced growth factors. 
  • Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Expanding indications for conservative renal surgery in renal cell carcinoma. 
  • Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. 
  • Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. 
  • Factors associated with improved survival following surgery for renal cell carcinoma spinal metastases. 
  • Factors impacting survival in children with renal cell carcinoma. 
  • Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. 
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. 
  • First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. 
  • Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. 
  • Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma: does ploidy status enhance prognostic stratification over stage alone? 
  • Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis. 
  • Functional computed tomography imaging of tumor-induced angiogenesis: preliminary results of new tracer kinetic modeling using a computer discretization approach. 
  • Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility. 
  • Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. 
  • Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. 
  • Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 
  • Hereditary renal cell carcinoma in the Eker rat: a unique animal model for the study of cancer susceptibility. 
  • Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6. 
  • High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit
. 
  • High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. 
  • High-dose interleukin-2 therapy related adverse events and implications on imaging. 
  • Histogram analysis of small solid renal masses: differentiating minimal fat angiomyolipoma from renal cell carcinoma. 
  • How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery. 
  • How we treat brain metastases in metastatic renal cell carcinoma. 
  • Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. 
  • Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. 
  • Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. 
  • Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. 
  • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. 
  • Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. 
  • Immunotherapy of surgical malignancies. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. 
  • Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. 
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. 
  • Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. 
  • Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. 
  • Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. 
  • Increased susceptibility to in vitro transformation of cells carrying the Eker tumor susceptibility mutation. 
  • Inflammatory protein profile during systemic high dose interleukin-2 administration. 
  • Information Transparency in the Drug Approval Process. 
  • Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. 
  • Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. 
  • Intraoperative transesophageal echocardiography diagnosis of residual tumor fragment after surgical removal of renal cell carcinoma. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study. 
  • Irreversible Electroporation for the Treatment of Small Renal Masses: 5-Year Outcomes. 
  • Is tumor response important for renal carcinoma? 
  • Kidney cancer. 
  • Kidney cancer. Clinical practice guidelines in oncology. 
  • Kidney cancer. Clinical practice guidelines. 
  • Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a 5-year, single-surgeon experience. 
  • Laparoscopic nephron-sparing surgery in a Jehovah's Witness patient. 
  • Laparoscopic radiofrequency ablation of small renal tumors: long-term oncologic outcomes. 
  • Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma. 
  • Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. 
  • Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. 
  • Mammalian target of rapamycin inhibition. 
  • Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. 
  • Management of small renal tumors with radiofrequency ablation. 
  • Management of small renal tumors: an overview. 
  • Mechanism of immune response during immunotherapy. 
  • Metastases in the pancreas from nonhematologic neoplasms: report of 20 cases evaluated by fine-needle aspiration. 
  • Metastatic Renal Cell Carcinoma to the Spine: Outcomes and Morbidity: Single-Center Experience. 
  • Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. 
  • Microwave ablation of cT1a renal cell carcinoma: oncologic and functional outcomes at a single center. 
  • Minimally Invasive Muscle Sparing Posterior-Only Approach for Lumbar Circumferential Decompression and Stabilization to Treat Spine Metastasis--Technical Report. 
  • Minimally invasive surgery using ablative modalities for the localized renal mass. 
  • Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. 
  • Molecular genetics and histopathologic features of adult distal nephron tumors. 
  • Multiple bilateral oncocytomas of the native kidneys following renal transplantation: report of a rare case and review of the literature. 
  • Multiple nephron-sparing procedures in solitary kidney with recurrent, metachronous, nonfamilial renal cell carcinoma. 
  • Mutagenicity and carcinogenicity of biological reactive intermediate's derived from a "non-genotoxic" carcinogen. 
  • Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. 
  • Natural history of renal cell carcinoma. 
  • Nephron-sparing surgery and renal cell carcinoma. 
  • Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. 
  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 
  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. 
  • Normothermic cardiopulmonary bypass with beating heart for management of renal cell carcinoma with atrial tumor thrombus. 
  • Novel antiangiogenic therapies for renal cell cancer. 
  • Novel immunotherapeutic strategies in development for renal cell carcinoma. 
  • Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. 
  • Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). 
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. 
  • PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. 
  • PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. 
  • Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature. 
  • Partial nephrectomy: technique, complications and pathological findings. 
  • Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. 
  • Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. 
  • Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. 
  • Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. 
  • Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma. 
  • Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 
  • Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 
  • Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. 
  • Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer. 
  • Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α. 
  • Predicting occult multifocality of renal cell carcinoma. 
  • Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 
  • Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 
  • Preneoplastic and neoplastic lesions of rat hereditary renal cell tumors express markers of proximal and distal nephron. 
  • Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. 
  • Preoperative transarterial embolization of spinal column neoplasms. 
  • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. 
  • Problems with the randomized discontinuation design. 
  • Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. 
  • Prognostic factors in renal adenocarcinoma. 
  • Prognostic factors in renal cancer. 
  • Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. 
  • Progression of renal tumors after laparoscopic radiofrequency ablation. 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? 
  • Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. 
  • Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. 
  • Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux. 
  • Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. 
  • Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). 
  • Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. 
  • Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. 
  • Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature. 
  • Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. 
  • Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. 
  • Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. 
  • Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. 
  • Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma. 
  • Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. 
  • Renal Transplantation with grafts affected by tumors: learning from a 'near miss' case. 
  • Renal carcinoma: detection of venous extension with gradient-echo MR imaging. 
  • Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus. 
  • Renal cell carcinoma suspected at time of organ donation 2008-2016: A report of the OPTN ad hoc Disease Transmission Advisory Committee Registry. 
  • Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. 
  • Renal cell carcinoma. 
  • Renal epithelial dysplasia. 
  • Renal tumors: diagnostic and prognostic biomarkers. 
  • Reply to B. Rini et al and S. Buti et al. 
  • Reply to M A Khattak et al. 
  • Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? 
  • Revisiting the Warburg Effect: Some Tumors Hold Their Breath. 
  • Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. 
  • Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. 
  • Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. 
  • Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. 
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. 
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. 
  • Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset? 
  • Secretion of a large molecular-weight form of insulin-like growth factor by a primary renal tumor. 
  • Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. 
  • Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. 
  • Setting a new standard for long-term survival in metastatic kidney cancer. 
  • Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. 
  • Signal integration and gene induction by a functionally distinct STAT3 phosphoform. 
  • Significant responses to platinum-based chemotherapy in renal medullary carcinoma. 
  • Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. 
  • Solitary renal cell carcinoma metastasis to the hand: the need for wide excision or amputation. 
  • Soluble B7-H1: differences in production between dendritic cells and T cells. 
  • Sonography of small renal masses with indeterminant density characteristics on computed tomography. 
  • Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Sunitinib efficacy against advanced renal cell carcinoma. 
  • Sunitinib in patients with metastatic renal cell carcinoma. 
  • Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. 
  • Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma. 
  • Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. 
  • Surgical management and prognosis of renal cell carcinoma invading the vena cava. 
  • Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. 
  • Synchronous clear cell renal cell carcinoma and tubulocystic carcinoma: genetic evidence of independent ontogenesis and implications of chromosomal imbalances in tumor progression. 
  • Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 
  • Targeted therapy in renal cell carcinoma. 
  • Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney. 
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. 
  • The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. 
  • The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. 
  • The Immunotherapy Landscape in Renal Cell Carcinoma. 
  • The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. 
  • The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials. 
  • The detection of renal carcinoma extension into the renal vein and inferior vena cava: a prospective comparison of venacavography and magnetic resonance imaging. 
  • The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma. 
  • The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. 
  • The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? 
  • The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. 
  • The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. 
  • The significance of septations in a renal cyst. 
  • The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). 
  • The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma. 
  • The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • The von Hippel-Lindau tumor suppressor gene and kidney cancer. 
  • The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. 
  • Therapeutic options for variant renal cancer: a true orphan disease. 
  • Therapy for non-clear cell histologies in renal cancer. 
  • Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. 
  • Tokuhashi score is predictive of survival in a cohort of patients undergoing surgery for renal cell carcinoma spinal metastases. 
  • Treatment of localised renal cell carcinoma. 
  • Treatment of osseous metastases in patients with renal cell carcinoma. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? 
  • Treatment strategies in renal carcinoma. 
  • Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. 
  • Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. 
  • Tyrosine kinase inhibitors in renal cell carcinoma. 
  • Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. 
  • Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma. 
  • Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the AJR Special Series on Cancer Staging. 
  • Ureteropelvic junction obliteration resulting in nephrectomy after radiofrequency ablation of small renal cell carcinoma. 
  • Urinary aquaporin 1 and perilipin 2: Can these novel markers accurately characterize small renal masses and help guide patient management? 
  • Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. 
  • Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer. 
  • Urothelial sloughing with obstruction after laparoscopic cryoablation of small renal carcinoma in solitary kidney. 
  • Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. 
  • VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? 
  • VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. 
  • Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. 
  • Zinc transporter ZIP7 is a novel determinant of ferroptosis. 
  • mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. 
  • p53 status in spontaneous and dimethylnitrosamine-induced renal cell tumors from rats. 
• 

  Keywords of People

  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Inman, Brant Allen, Professor of Surgery, Surgery, Urology